" the Regoranfenib Post & other new drugs"

But some outliers lasted a year and some died earlier. But it was around 5 months for placebo and 6 for the treatment group.

Best

Regoranfenib Here! specially hear about effectiveness and secondary effects so is very important for most of us to know about you!
By the way have you started ? if so any special effect ?.
Hugs my friend!

Have been reading a bit on these lately and thought I would post my interpretation of the data so far:

Regorafenib (Reg, hear forward to save typing)- is a blocker of VEGF receptor so works in the same pathway as Avastin (which binds VEGF A) aiming to interfere with development of new blood vessels in tumours. The big phase III trial described is certainly significant despite the confusing finding it only increased median survival by 1.4 months. The patient group , as described above, were a very late group who had not responded to all other treatments whose life expectancy was very short. It was extended by almost a third by the drug.In this group almost none (1%) 'responded' ie saw tumour shrinkage, but a good number had their disease stabilised- a good outcome in this group. It needs testing on earlier phases with more data on other end points- quality of life beingone of them. They are also investigating subgroups with the feeling there is a likely group of peoplpe who benefit (bit like the KRAS issue with cetuxamab).

Aflibercept- is described as a VEGF trap- it binds VEGF A and B and other factors that promote angiogenesis (blood vessel development). It is therefore being promoted as being able to do more than avastin. It too has a phase III trial (VELOUR) in 1226 patients treated with either FOLFIRI with placebo or FOLFIRI with aflibercept. Again survival was improved by about 1.5 months and progression free survival (stable disease period) was increased by 2.2 months. There was also a higher 'response rate' of 19.8% in the treatment group (11.1% in placebo) which is something the Reg study didn't find (though in different patient groups). The side effect profile does concern me though with Aflibercept with high rates of renal problems and hypertension.It is now being studied with FOLFOX.

Both are very important developments and I think there will be a race to get them approved and find a place in the protocols. They will initially be used late in protocols after others fail but as more studies are done in ealier groups they may move up the algorithms.

I do think people's experiences with these drugs MUST be reported here as they are invaluable to many of us.If people feel discouraged from doing so it is a huge loss to many of us interested in these drugs. They are truly the first big developments since avastin in a field that has been quiet for too long. For many of us they offer hope- that is vital.

steve